Literature DB >> 25304310

The role of poly(ADP-ribose) polymerase-1 inhibitor in carrageenan-induced lung inflammation in mice.

Sheikh Fayaz Ahmad1, Khairy M A Zoheir2, Mushtaq Ahmad Ansari3, Hesham M Korashy3, Saleh A Bakheet3, Abdelkader E Ashour3, Othman A Al-Shabanah3, Mohammed M Al-harbi3, Sabry M Attia4.   

Abstract

Increasing indication is unveiling a role for poly(ADP-ribose) polymerase (PARP)-1 in the regulation of inflammatory/immune responses. The aim of the present study was to determine the potential anti-inflammatory effects of PARP-1 inhibitor 5-aminoisoquinolinone (5-AIQ) to explore the role of PARP-1 inhibitor in a mouse model of carrageenan-induced lung inflammation. A single dose of 5-AIQ (1.5mg/kg) was administered intraperitoneally (i.p.) 1h before λ-carrageenan (Cg) administration. We assessed the effects of 5-AIQ treatment on CD25(+), GITR(+), CD25(+)GITR(+), IL-17(+) and Foxp3(+) cells which were investigated using flowcytometry in pleural exudates and heparinized blood. We also evaluated mRNA expressions of IL-6, TNF-α, IL-1β, IL-10, CD11a, l-selectin (CD62L), ICAM-1, MCP-1, iNOS and COX-2 in the lung tissue. We further examined the effects of 5-AIQ on the key mediators of inflammation, namely COX-2, STAT-3, NF-kB p65, PARP-1, IkB-α and IL-4 protein expression in the lung tissue using western blotting. The results illustrated that the numbers of T cell subsets, IL-17(+) cytokine levels were markedly increased and Foxp3(+) production decreased in the Cg group. Furthermore, Cg-induced up-regulation of adhesion molecules, pro-inflammatory mediators and chemokine expressions. Western blot analysis revealed an increased protein expressions of COX-2, STAT-3 NF-kB p65 and PARP-1 and decreased IkB-α and IL-4 in the Cg group. PARP-1 inhibitor via 5-AIQ treatment reverses the action significantly of all the previously mentioned effects. Moreover, histological examinations revealed anti-inflammatory effects of 5-AIQ, whereas Cg-group aggravated Cg-induced inflammation. Present findings demonstrate the potent anti-inflammatory action of the PARP-1 inhibitor in acute lung injury induced by carrageenan.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carrageenan; Inflammatory mediators; Lung tissue; PARP-1 inhibitor; Pleural exudate

Mesh:

Substances:

Year:  2014        PMID: 25304310     DOI: 10.1016/j.molimm.2014.09.009

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  11 in total

1.  The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.

Authors:  Akbar Ahmad; Gabor Olah; David N Herndon; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-05       Impact factor: 8.739

2.  Resveratrol Improves Neuroimmune Dysregulation Through the Inhibition of Neuronal Toll-Like Receptors and COX-2 Signaling in BTBR T+ Itpr3tf/J Mice.

Authors:  Sheikh F Ahmad; Mushtaq A Ansari; Ahmed Nadeem; Mohammad Z Alzahrani; Saleh A Bakheet; Sabry M Attia
Journal:  Neuromolecular Med       Date:  2018-02-21       Impact factor: 3.843

3.  A Hepatocellular Carcinoma Patient with TSC1 Mutations Benefits from Treatment with Everolimus: A Case Report.

Authors:  Hua-Sheng Shi; Shuo Wang; Man-Jiang Li; Li-Qun Wu
Journal:  Visc Med       Date:  2020-05-27

Review 4.  ADP-ribosylation in evasion, promotion and exacerbation of immune responses.

Authors:  Maria Manuela Rosado; Claudio Pioli
Journal:  Immunology       Date:  2021-04-12       Impact factor: 7.215

5.  The relevance of theobromine for the beneficial effects of cocoa consumption.

Authors:  Eva Martínez-Pinilla; Ainhoa Oñatibia-Astibia; Rafael Franco
Journal:  Front Pharmacol       Date:  2015-02-20       Impact factor: 5.810

6.  Nicotinamide exacerbates hypoxemia in ventilator-induced lung injury independent of neutrophil infiltration.

Authors:  Heather D Jones; Jeena Yoo; Timothy R Crother; Pierre Kyme; Anat Ben-Shlomo; Ramtin Khalafi; Ching W Tseng; William C Parks; Moshe Arditi; George Y Liu; Kenichi Shimada
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

7.  PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.

Authors:  Mohamed A Ghonim; Kusma Pyakurel; Salome V Ibba; Jeffrey Wang; Paulo Rodriguez; Amir A Al-Khami; Matthew R Lammi; Hogyoung Kim; Arnold H Zea; Christian Davis; Samuel Okpechi; Dorota Wyczechowska; Kamel Al-Ghareeb; Moselhy S Mansy; Augusto Ochoa; Amarjit S Naura; A Hamid Boulares
Journal:  Clin Sci (Lond)       Date:  2015-07-23       Impact factor: 6.124

Review 8.  Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?

Authors:  Nicola Curtin; Krisztián Bányai; James Thaventhiran; John Le Quesne; Zsuzsanna Helyes; Péter Bai
Journal:  Br J Pharmacol       Date:  2020-07-05       Impact factor: 8.739

9.  Protective Effect of Piceatannol Against Acute Lung Injury Through Protecting the Integrity of Air-Blood Barrier and Modulating the TLR4/NF-κB Signaling Pathway Activation.

Authors:  Lu-Yuan Peng; Meng Yuan; Hai-Tao Shi; Jing-He Li; Ke Song; Jiang-Ni Huang; Peng-Fei Yi; Ben-Dong Fu; Hai-Qing Shen
Journal:  Front Pharmacol       Date:  2020-01-22       Impact factor: 5.810

10.  PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier.

Authors:  Slava Rom; Viviana Zuluaga-Ramirez; Nancy L Reichenbach; Holly Dykstra; Sachin Gajghate; Pal Pacher; Yuri Persidsky
Journal:  J Neuroinflammation       Date:  2016-09-27       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.